The availability of the tyrosin kinase inhibitor imatinib which not only targets bcr/abl but also c-kit and PDGFR has led to investigate the participation of these two receptors in several solid malignancies, particularly in small cell lung cancer and prostate carcinoma which over-express the c-kit receptor. The gene discussed is PDGFRB; the disease is prostate carcinoma.